pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

12 catalysts · 4 phase 2 completion · 3 phase 1 completion · 2 phase 1 initiation · 1 constraining patent expiry europe · 1 patent expiry · 1 phase 1 2 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 21 catalysts2026-07-30: 12 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 1 catalyst2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
TA: multiple-sclerosis×TA: infectious-disease×clear all
type
  • phase 2 completion4
  • phase 1 completion3
  • phase 1 initiation2
  • constraining patent expiry europe1
  • patent expiry1
phase 1 2 completion
1
therapy area
  • Oncology87
  • Cardiology23
  • Immunology15
  • Infectious Disease12
  • Dermatology12
  • Ophthalmology8
  • Women's Health8
  • Pulmonology8
  • Pain6

Week of Apr 27, 2026

12
›Apr 30, 2026constraining patent expiry europe91d agoCumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))telavancin hydrochloride

Therapy area: Cardiovascular, Dermatology, Infectious Disease, Respiratory. Indication: Anthrax, Bacteremia, Bacterial Endocarditis, Bacterial Pneumonia, Complicated Skin And Skin Structure Infections (cSSSI), Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections, Hospital Acquired Pneumonia (HAP), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Skin And Soft Tissue Infections, Ventilator Associated Pneumonia (VAP)

full page →telavancin hydrochloride →source: globaldata
›Apr 30, 2026patent expiry91d agoBasilea Pharmaceutica Ltd — isavuconazonium sulfate (Constraining Patent Expiry (US))isavuconazonium sulfate

Therapy area: Infectious Disease. Indication: Aspergillosis, Candidiasis, Cryptococcal Meningitis, Cryptococcosis, Zygomycosis (Mucormycosis)

full page →isavuconazonium sulfate →source: globaldata
›Apr 30, 2026phase 1 completion91d agoShenzhen Digestive System Disease Clinical Medicine Research Center — tegoprazan (Phase I Trial Completion)tegoprazan

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →tegoprazan →source: globaldata
›Apr 30, 2026phase 1 completion91d agoMAXVAX Biotechnology Co Ltd — MKK-900 (Phase I Trial Completion)MKK-900

Therapy area: Infectious Disease. Indication: Respiratory Syncytial Virus (RSV) Infections

full page →MKK-900 →source: globaldata
›Apr 30, 2026phase 1 completion91d agoJohns Hopkins University — ciprofloxacin (Phase I Trial Completion)ciprofloxacin

Therapy area: Infectious Disease. Indication: Bacillary Dysentery (Shigellosis)

full page →ciprofloxacin →source: globaldata
›Apr 30, 2026phase 1 initiation91d agoGilead Sciences Inc — GS-1701 (Phase I Trial Initiation)GS-1701

Therapy area: Infectious Disease. Indication: Unspecified Infectious Diseases

full page →GS-1701 →source: globaldata
›Apr 30, 2026phase 1 initiation91d agoThe National Institute of Allergy and Infectious Diseases — dasatinib (Phase I Trial Initiation)DASATINIB

Therapy area: Infectious Disease. Indication: Human Immunodeficiency Virus (HIV) Infections (AIDS)

full page →DASATINIB →source: globaldata
›Apr 30, 2026phase 1 2 completion91d agoUniversity Hospital Geneva — verteporfin (Phase I/II Trial Completion)verteporfin

Therapy area: Dermatology, Infectious Disease, Oncology. Indication: Melanoma, Scar, Surgical Wound Infections

full page →verteporfin →source: globaldata
›Apr 30, 2026phase 2 completion91d agoQinghai Provincial Xining Third People's Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Gastrointestinal, Infectious Disease. Indication: Gastritis, Helicobacter pylori Infections

full page →amoxicillin →source: globaldata
›Apr 30, 2026phase 2 completion91d agoNational Institutes of Health — metformin hydrochloride ER (Phase II Trial Completion)metformin hydrochloride ER

Therapy area: Cardiovascular, Genito Urinary System, Infectious Disease. Indication: Acute Renal Failure (ARF) (Acute Kidney Injury), Sepsis, Septic Shock

full page →metformin hydrochloride ER →source: globaldata
›Apr 30, 2026phase 2 completion91d agoNanjing First Hospital — amoxicillin (Phase II Trial Completion)amoxicillin

Therapy area: Infectious Disease. Indication: Helicobacter pylori Infections

full page →amoxicillin →source: globaldata
›Apr 30, 2026phase 2 completion91d agoInstituto de Investigacion sanitaria de Santiago de Compostela — Vacucis (Phase II Trial Completion)Vacucis

Therapy area: Infectious Disease, Mouth and Dental Disorders. Indication: Candidiasis, Xerostomia

full page →Vacucis →source: globaldata
$CPIX6.8100-3.13%
$GILD134.32+2.91%